https://doi.org/10.31288/oftalmolzh201424954

Change of clinical indices in patients with the dry form of age-related macular degeneration

A. M. Petrunya, O. A. Evsyukova

Lugansk State Medical University, Lugansk (Ukraine)

Key words: age-related macular degeneration (AMD), clinical indices

Introduction. Age-related macular degeneration (AMD) is a frequent cause of irreversible blindness in persons of advanced age and possesses high prevalence and propensity to progressing.

Material and methods. Disturbances of clinical indices in 108 patients with the dry form of age-related macula degenerations was investigated.

Results. Visual acuity in patients of the basic group was 0.53+0.06 that was lower (p<0.01) than indices of the control group (0.05). Total field of vision was (518.0+0.3) degrees that was lower (p<0.01) than indices of the control group. There was reduction of the level of CFFF up to (34.7+0.2) Hz that was lower (p<0.05) than the indices of the control group, the level TES by PH has made (96.6+0.2) mcA that was higher (p<0.05) in comparison with indices of the control group, there was reduction in the level of CFFD by PH up to (37.8+0.2) Hz that was lower (p<0.05) in comparison with indices of the control group. Lengthening of the time of restoration of visual acuity after photostress — test was noted up to (63.3+0.5) s that exceeded (p<0.01) indices of the control group.

Conclusion. There was established reduction (p<0.01) of visual acuity, total field of vision, reduction in the level of CFFF, increase in the level of TES by PH and reduction of CFFD by PH in comparison with indices of the control group (p<0.01), as well as lengthening of the time of restoration of visual acuity by carrying out photostress -test.

References

1.Astakhov YuS, Butin EV, Morozova NV, Sokolov VO. Rating retinalamine neuroprotective effect in the treatment of patients with primary open-angle glaucoma. Retinalamine. Neuroprotection in ophthalmology. Maksimov IB, Neroiev VV, editors. SPb.: Nauka; 2007. 38- 46.

2.Astakhov YuS, Lisochkina AB, Shadrichev FE. Age-related macular degeneration. Ophthalmology: national guidance. Under edition of Avetisov SE, Moshetova LK, Neroiev VV, Takhchidi KhP. M.:GEOTAR-Media; 2008.

3.Boiko EV. Zhuravleva LV. Experience of using «Lutein forte» in the treatment of «dry» form of age-related macular degeneration. Klin Oftalmologiia. 2007; 8:2. Russian.

4.Vervelskaya VM, Lebenkova OA. Features of the critical frequency and the frequency-contrast sensitivity of the eye to color in optic atrophy. Current issues of social ophthalmology. M.; 1998. 43-7.

5.Golubtsov KV, Kliman IG, Khelo TS, Shigina NA, Trunov VG, Aidu EA-I, Bykova TA, Sofronov PD, Ryabtseva AA. Flickering light in the diagnosis and treatment of pathological processes of the human visual system. Infor-mation processes. 3(2). 114-122.

6.Yegorova TE. Antioxidants in the treatment and prevention of the dry form of age-related macular degeneration. Review. Klin Oftalmologiia. 2010;11(2):69-71. Russian.

7.Libman ES, Shakhova EV. Blindness, visual impairment and disability in the Russian Federation. Proceedings of Russian interregional symposia. Ufa. 2003. 38-42.

8.Libman ES, Shakhova EV. Blindness and disability caused by eye pathology in Russia. Vestn Oftalmol. 2006;1:35-7. Russian.

9.Maichuk YuF. Principles of the WHO worldwide initiative to eliminate avoidable blindness. Possible ways of using them in the Russian Federation. Okulist. 2003;44(4):5-8. Russian.

10.Mikhina MA, Sotnikova EV, Kutepova OM. Social significance and relevance of macular dystrophy treatment. Proceedings of VII Congress of Ophthalmologists of Russia. M.;2000.

11.Pasyechnikova NV, Korol AR. Clinical classification and treatment strategy in patients with age-related macular degeneration. Oftalmol Zh. 2010;2:38-41. Russian.
Crossref

12.Ponomarchuk VS, Ivanov VA, Fiadoyer S. Method and device for differential diagnosis of pathological conditions of the retina. Oftalmol Zh. 1990;8:451-5. Russian.

13.Tovkach VI. Photostress by ordinary electroophthalmoscope in the diagnosis of eye diseases. Voiennyi meditsinskii zhurnal. 1977;8:40-4. Russian.

14.Congdon N, O'Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004;122:477- 85.
Crossref

15.Friedman E et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995;102(4): 640-6.
Crossref

16.Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. 2000;130(5):658- 63.
Crossref

17.Klein R, Klein BE, Knudtson MD et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology.2006;113:373-80.
Crossref

18.Pierce, E. A. Prophylactic treatment of drusen in AMD / E. A. Pierce // Bio Essay — 2001. — Vol. 23. — P. 605- 618.
Crossref

19.Resnikoff S et al. Bulletin of the World Health Organization. 2004;82(11):844-51.

20.Williamson TH, Harris A. Color Doppler ultrasound imaging of the eye and orbit. Surv. Ophthalmol. 1996;40:255.
Crossref

21.Wu G, Weiter JJ, Santos S et al. The macular photostress test indiabetic retinopathy and age-related macular degeneration. Arch.Ophthalmol. 1990;108:1556-8.
Crossref